A ‘Scheme Hiding in Plain Sight’Taking to X in a recent video post, Scaramucci called the initiative a "scheme hiding in plain sight, and almost no one’s talking about it."
He directly accused the company of facilitating an uneven playing field for the financial sector at the direct expense of regular traders. "Truth Social is going to sell hedge fund managers millisecond advantages on Trump’s tweets so that they can front-run other people’s trades," Scaramucci warned.
Not a Loophole, But a FeatureInterim CEO Kevin McGurn embraced the platform’s financial influence as a selling point, stating, “Markets already move on Truth Social posts.” He added that the API advances their strategy to monetize assets through a “high-margin, recurring revenue stream.”
However, Scaramucci emphasized that this inequity is entirely by design. "It’s not a loophole, it’s a business model, and we’ve got 30 months left to live with it," he wrote. Expressing sheer disbelief in his video, Scaramucci remarked, "It’s unbelievable what’s actually going on. So I find it like driving 30 months in a lemon of a car. Time, guys."
Benzinga has reached out to Trump Media & Technology Group for comment on Scaramucci’s allegations but did not receive an immediate response.
How Has DJT Performed In 2026?DJT shares were down 25.83% year-to-date, but 15.67% higher over the last month, and down 48.99% over the year. It closed up 0.82% at $9.82 per share on Tuesday, and it was 0.61% lower in overnight trading.
Benzinga’s Edge Stock Rankings indicate that DJT maintains a strong price trend in the short and medium terms but a weak trend in the long term.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: mundissima / Shutterstock
Market News and Data brought to you by Benzinga APIs
Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities.
On a call with analysts, Tempus said it agreed to acquire all outstanding shares of Personalis not already owned by Tempus at $16.25 per share. The company said the price represents a 6% premium to Personalis’ Friday closing price and a 28% premium to its unaffected 30-day volume-weighted average price.
The consideration is structured as 100% stock, though Tempus has the option to pay up to 50% in cash. Personalis shareholders would receive a floating exchange ratio of Tempus common stock for each Personalis share held at closing, subject to a maximum exchange ratio of 0.3356. Tempus said any cash portion could be financed with cash on hand and additional borrowing procured between signing and closing. The companies expect the transaction to close in late 2026 or early 2027.
Tempus Points to MRD Growth and Reimbursement Momentum Tempus said Personalis’ NeXT Personal offering has seen strong adoption, with quarter-over-quarter growth of 38%. The company said volumes could become “even more material and higher” as additional sales representatives are equipped to sell the offering and as more indications secure reimbursement.
In response to a question from Kallum Titchmarsh of Morgan Stanley, an executive identified as Eric said Tempus is “quickly gaining market adoption,” citing both overall growth in the MRD market and the performance of Personalis’ assay. He said Tempus expects to embed more of its technology into the MRD offering over time, including hospital connectivity, AI-enabled ordering tools and AI-derived insights.
Eric said Tempus has so far been selective in allowing its sales force to carry the MRD product, with roughly 10% of sales representatives currently involved. He said the company expects to expand that access as more indications receive reimbursement.
Why Tempus Says the Timing Is Right Asked by Kyle Mikson of Canaccord Genuity why Tempus is pursuing the acquisition now, Eric said the company had reviewed Personalis in 2023 but opted at that time for a commercial agreement because Personalis still faced several years of heavy investment. He said Personalis has since advanced the assay and is entering a phase in which coverage and reimbursement should improve the economics of the tests.
Eric said MRD assays can move from generating little or no revenue in certain uses to producing significant revenue after analytic validity, clinical validity, publication and MolDX approval requirements are met. He said Personalis is now entering that part of the cycle, and Tempus expects its financial profile to improve.
Jim Rogers, CFO and Treasurer of Tempus AI, said the company’s core business has “good tailwinds” from therapy selection volume growth and average selling price improvements. He said Tempus is generating incremental gross profit dollars and had already intended to reinvest a portion of that into the business, with MRD as a major investment area.
Data and Biopharma Opportunities Tempus said the Personalis portfolio also enhances its biopharma offering through profiling and immuno-oncology capabilities. The company highlighted the potential value of de-identified longitudinal MRD data, saying serial measurements can reveal disease dynamics, treatment response, resistance and recurrence, which may support biomarker discovery, patient selection and trial optimization.
Eric said the prior relationship between the companies gave Tempus broad clinical distribution rights, while Personalis retained its own biopharma business and data rights. After closing, he said Tempus expects to more tightly combine those capabilities, which he said could be “catalytic” to both companies’ pharma businesses.
Rogers added that Tempus already has a large biopharma data business and does sequencing for biopharma customers. He said integrating Personalis’ biopharma business with Tempus’ current offering could help expand overall relationships with biopharma clients.
Financial Targets Remain in Place Tempus said it will provide more detail on the transaction’s financial impact and outlook during its second-quarter earnings call on July 30. Despite the acquisition, the company said it intends to be adjusted EBITDA and free cash flow positive in 2027.
Asked about margins and reimbursement by Mark Massaro of BTIG, Eric said Tempus was not ready to provide extensive detail on Personalis’ business before a future update, but said Personalis is collecting clinical-side reimbursement dollars. He added that Tempus would not have agreed to the acquisition if it did not believe the margin profile would become “super healthy.”
Elizabeth Krutoholow, Tempus AI’s Vice President of Investor Relations, closed the call by thanking participants and said the company expects to speak with investors again on its July 30 second-quarter call.
About Tempus AI (NASDAQ:TEM) Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
« PREVIOUS HEADLINEBank Stocks To Add to Your Watchlist – July 20th
NEXT HEADLINE »Best Mining Stocks To Add to Your Watchlist – July 20th
MCLEAN, Va.--(BUSINESS WIRE)--As federal agencies rapidly adopt agentic AI systems capable of acting autonomously, a new Booz Allen survey released today reveals a growing gap between deployment and trust. The findings are featured in the latest issue of Velocity, Booz Allen's regular publication exploring emerging technology and mission innovation. This edition focuses specifically on how AI is transforming the mission and cyber technology stack and outlines the systems-level approach organiza.
NEW YORK--(BUSINESS WIRE)--Pagaya Technologies Ltd. (NASDAQ: PGY) (“Pagaya”), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced that the Company's management team will participate in the following investor conference: CG 46th Annual Growth Conference Date: August 11, 2026 Location: Boston, MA Webcast: Click here to register and listen to a live fireside at 4:30pm ET on August 11, 2026. About Pagaya Technologies Pagaya (NASDAQ: PGY) i.
GE Vernova Inc. (NYSE:GEV) will release its second quarter earnings report before the opening bell on Wednesday, July 22.
Analysts expect the Cambridge, Massachusetts-based company to report quarterly earnings of $3.19 per share, up from $1.86 per share in the year-ago period. The consensus estimate for GE Vernova’s quarterly revenue is $10.76 billion. It reported $9.11 billion last year, according to Benzinga Pro.
On July 7, GE Vernova, Hitachi, Samsung C&T and SGE signed an agreement over deployment of BWRX-300 SMR throughout Europe.
Shares of GE Vernova slipped 0.1% to close at $1,078.81 on Tuesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Considering buying GEV stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Equinor (OSE:EQNR, NYSE:EQNR) delivered an adjusted operating income* of USD 11.48 billion in the second quarter of 2026. Equinor reported a net operating income of USD 12.99 billion and a net income of USD 4.84 billion. Adjusted net income* was USD 3.22 billion, leading to adjusted earnings per share* of USD 1.33.
Delivering on strategy: more energy, growing cash flow and superior returns
Contracts awarded for first wave of NCS tie-back projectsStrategic transactions on the NCS to harmonise ownership and progress Ringvei VestFID taken for Greater PAJ in Angola
Strong production, cash flow and financial results
Production growth of 3%High value creation from asset-backed tradingCash flow from operations after taxes paid* of USD 7.7 billion
Capital distribution
Second quarter cash dividend of USD 0.39 per shareThird tranche of the share buy-back of up to USD 1,125 millionExpected share buy-back of USD 3 billion for 2026
Anders Opedal, President and CEO of Equinor ASA:
“Strong production in the second quarter enabled us to capture value from higher prices, contributing to strong cash flow and financial results.”
“We made progress on our priorities set out at the Capital Markets Day to deliver more energy, growing cash flow and superior returns. In the quarter, we strengthened our portfolio through project execution and strategic transactions.”
“Reliable energy is important in a volatile world marked by heightened geopolitical tension. Our role is to deliver energy safely and efficiently every day.”
More energy through strong production
Equinor delivered high production in the second quarter with a total equity production of 2,165 mboe per day in the second quarter. This is a 3% increase compared to 2,096 mboe per day in the same quarter last year.
Production from new fields, including Eirin and Symra coming on stream, drove a 4% production increase on the Norwegian continental shelf (NCS) compared to the second quarter of 2025. Johan Sverdrup and new wells supported the production, while planned turnaround activity and natural decline partially offset the result.
The addition of production from Adura in the UK and the Bacalhau field in Brazil, as well as lower turnaround activity, contributed to a 4% production increase in the international oil and gas reporting segment compared to the same period last year. This was partially offset by portfolio changes, in addition to natural decline and operational issues at Roncador in Brazil.
The production in the US was stable in the quarter compared to the same quarter last year.
Total power generation was 1.19 TWh. Driven by Dogger Bank B and new onshore assets, renewable power generation increased by 11% compared to the second quarter of 2025. The increase in total power generation was partially offset by lower gas-to-power generation.
Growing cash flow with strong financial results
Equinor delivered an adjusted operating income* of USD 11.48 billion and USD 3.44 billion after tax* in the second quarter. The results are primarily impacted by higher liquid prices globally and European gas prices, partially offset by lower US gas prices.
The reported net operating income of USD 12.99 billion is up from USD 5.72 billion in the same quarter last year. Results were supported by higher prices, positive derivative effects and the sale of assets in Argentina.
Equinor realised a European gas price of USD 15.8 per mmbtu and a liquids price of USD 97.9 per bbl in the second quarter.
The Marketing, Midstream and Processing results were strong, primarily driven by strong crude trading and refining performance.
Adjusted operating and administrative expenses* were higher compared to the same quarter last year. This was mainly due to higher transportation costs from increased freight rates and currency effects.
High production combined with higher prices generated cash flows provided by operating activities, before taxes paid and working capital items, of USD 14.75 billion.
In the quarter, Equinor paid the final three NCS tax instalments for 2025 totalling USD 6.4 billion.
Cash flow from operations after taxes paid* ended at USD 7.68 billion.
Organic capital expenditure* was USD 3.35 billion and total capital expenditures were USD 3.57 billion.
The net debt to capital employed adjusted ratio* was 10.4% at the end of the second quarter, compared to 15.3% last quarter.
Executing on strategy
On the NCS, Equinor awarded contracts for the first wave of NCS tie-back projects and secured a series of strategic transactions to unlock additional value, accelerate development and strengthen the position in key areas.
Moreover, production started at both the Symra and the Eirin field, of which the latter is expected to extend the production from the Gina Krog platform by seven years.
In the quarter, Equinor, together with partners, took a final investment decision for the offshore oil development Greater PAJ project in Angola.
Equinor had exploration activity on ten wells in the quarter. Seven wells were completed, of which three appraisal wells on the NCS confirm previously reported commercial discoveries.
Capital distribution
The board of directors has decided a cash dividend of USD 0.39 per share for the second quarter 2026. This is in line with the communication on 4 February 2026, when results for the fourth quarter of 2025 were announced.
At the Capital Markets Day on 16 June this year, Equinor announced an intention to increase the share buy-back programme for 2026 by USD 1.5 billion. This brings the total expected programme for 2026 to up to USD 3 billion, including shares to be redeemed from the Norwegian State. The board has decided to initiate a third tranche of the share buy-back programme for 2026 of up to USD 1,125 million. The tranche will commence on 23 July and end no later than 26 October 2026.
The second tranche of the share buy-back programme for 2026 was completed on 16 July 2026 with a total value of USD 375 million.
All share buy-back amounts include shares to be redeemed by the Norwegian State.
- - -
*For items marked with an asterisk throughout this report, see Use and reconciliation of non-GAAP financial measures in the Supplementary disclosures.
Key information relating to the cash dividend to be paid by Equinor ASA (OSE: EQNR, NYSE: EQNR) for second quarter 2026.
Cash dividend amount: 0.39
Announced currency: USD
Last day including rights: 12 November 2026
Ex-date Oslo Børs: 13 November 2026
Ex-date New York Stock Exchange: 16 November 2026
Record date: 16 November 2026
Payment date: 25 November 2026
Date of approval: 21 July 2026.
Other information: The cash dividend per share in NOK will be communicated 20 November 2026.
This information is published in accordance with the requirements of the Continuing Obligations and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.
An Equinor sign is seen at the company's headquarters in Fornebu, Norway, May 21, 2018. REUTERS/Nerijus Adomaitis/File Photo Purchase Licensing Rights, opens new tab
SummaryCompaniesAdjusted pretax profit $11.48 billion vs forecast $11.37 billionYear-ago profit was $6.54 billionOil and gas prices soar on Iran warEquinor's shares up 54% year-to-date ahead of the earningsOSLO, July 22 (Reuters) - Equinor (EQNR.OL), opens new tab on Wednesday reported a sharp rise in second-quarter profits, as expected, lifted by a surge in oil and gas prices as the war in the Middle East disrupted global energy supplies.
The Norwegian group's adjusted earnings before tax for the April to June period rose to $11.48 billion from $6.54 billion a year earlier, broadly in line with the $11.37 billion predicted in a poll of 17 analysts compiled by Equinor.
The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.
"Strong production in the second quarter enabled us to capture value from higher prices, contributing to strong cash flow and financial results," CEO Anders Opedal said in a statement.
The shares of majority state-owned Equinor are up 54% year-to-date, outperforming a 30% increase in European energy stocks (.SXEP), opens new tab, reflecting its position as a major supplier of oil and gas to Europe and with no direct exposure to the Middle East.
The company last month said it will double its share buybacks, returning more cash to owners as the wartime rise in oil and gas prices filled its coffers, while at the same time scaling back investments in renewable energy due to weak demand.
Equinor maintained its full-year oil and gas output growth target of a 3% volume increase in 2026 as well as its planned investment level for the year of $13 billion.
The downstream division, which includes energy trading, reported a profit of $777 million for the quarter, exceeding the $623 million expected by analysts and beating the unit's $400 million quarterly profit guidance.
The average price for Equinor's oil stood at $97.9 per barrel in the second quarter, up from $63 in the same period of 2025.
The price for the group's European gas meanwhile increased by 32% over the same period to $15.79 per million British thermal units (mmbtu), while its U.S. gas price declined 16% to $2.30 per mmbtu.
Reporting by Nora Buli, editing by Terje Solsvik
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Second-quarter adjusted operating income jumped over 75% as the Norwegian energy major captured higher oil and gas prices triggered by the conflict in the Middle East.
Shares of Strive, Inc. (NASDAQ:ASST – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $28.00.
ASST has been the topic of a number of analyst reports. Weiss Ratings upgraded Strive from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 14th. TD Cowen restated a “buy” rating and issued a $30.00 target price (up from $28.00) on shares of Strive in a report on Monday, May 18th. Benchmark reaffirmed a “buy” rating on shares of Strive in a research note on Monday, June 15th. HC Wainwright lifted their price target on Strive from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Finally, Wall Street Zen raised shares of Strive from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th.
View Our Latest Stock Analysis on ASST
Strive Stock Up 5.3% Shares of NASDAQ ASST opened at $13.00 on Friday. Strive has a 12-month low of $7.02 and a 12-month high of $252.00. The stock has a market cap of $950.04 million, a PE ratio of -1.51 and a beta of 13.22. The company has a current ratio of 11.44, a quick ratio of 11.44 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average of $14.57 and a 200 day moving average of $13.49.
Strive (NASDAQ:ASST – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($5.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.70) by ($2.49). The business had revenue of $2.76 million during the quarter, compared to analysts’ expectations of $2.73 million. Strive had a negative return on equity of 139.10% and a negative net margin of 9,655.92%. As a group, sell-side analysts predict that Strive will post -4.11 EPS for the current fiscal year.
Hedge Funds Weigh In On Strive Institutional investors have recently bought and sold shares of the company. Thompson Davis & CO. Inc. purchased a new stake in shares of Strive in the 4th quarter valued at approximately $74,000. FNY Investment Advisers LLC raised its position in shares of Strive by 457,042.9% during the 4th quarter. FNY Investment Advisers LLC now owns 160,000 shares of the company’s stock valued at $118,000 after buying an additional 159,965 shares during the period. Gibbs Wealth Management purchased a new stake in shares of Strive during the 4th quarter valued at approximately $59,000. Trivium Point Advisory LLC acquired a new position in Strive in the fourth quarter valued at approximately $103,000. Finally, Institute for Wealth Management LLC. acquired a new position in Strive in the fourth quarter valued at approximately $26,000. 5.52% of the stock is owned by hedge funds and other institutional investors.
About Strive (Get Free Report)
Asset Entities, Inc (NASDAQ: ASST) is a specialty finance company that acquires, originates and services asset-backed loans and receivables across a range of industry sectors. The firm focuses on structuring and managing credit portfolios in equipment finance, commercial receivables and other asset-backed classes, employing securitization vehicles and bespoke financing solutions to deliver liquidity to underserved small- and mid-market borrowers.
Through its platform, Asset Entities leverages data-driven underwriting, risk management and portfolio optimization to create diversified exposure across end markets.
Featured Articles Five stocks we like better than Strive Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Strive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strive and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEDaiichi Sankyo (OTCMKTS:DSNKY) & Shuttle Pharmaceuticals (NASDAQ:SHPH) Head to Head Contrast
NEXT HEADLINE »Korn/Ferry International (NYSE:KFY) Receives $78.50 Consensus PT from Brokerages
Ceny českých potravin letos pokračují v jízdě plné překvapení. Společně s nápoji a tabákem v červnu meziročně klesaly o více než 1 %, přičemž samotné potraviny zlevnily o více než 3 %. Právě tento vývoj byl jedním z hlavních důvodů, proč celková inflace zpomalila z 2,1 % na 1,5 %. Pro nás to představovalo důvod k mírnému snížení odhadu inflace pro rok 2026. Z pohledu roku 2027 však nadále zůstáváme spíše pesimističtí. Další zlevňování potravin považujeme za neudržitelné a nízké ceny v letošním roce podle nás pouze vytvářejí prostor pro výraznější meziroční zdražování v roce příštím. Proč?
Za prvé, za letošním poklesem cen stojí především mléčné výrobky, tuky a některé vybrané masné produkty. Jednoznačným premiantem jsou mléko a máslo, kde Česko s určitým zpožděním kopíruje vývoj v Německu a cenové výkyvy navíc často ještě zesiluje. Mléko i máslo totiž bývají v českých obchodech pravidelně součástí slevových akcí. Jejich letošní zlevnění však nemá strukturální charakter. Jde především o důsledek předchozího výrazného růstu cen v letech 2024–2025, na který reagovala vyšší produkce, podpořená zároveň levnějšími krmivy. Nic z toho však není trvalého charakteru.
Za druhé, situaci zásadně mění i stále uzavřený Hormuzský průliv. Inflační šok spojený s Hormuzem by se časem měl promítnout také do cen potravin. Jednak prostřednictvím dražších hnojiv a vyšších nákladů rostlinné výroby, jednak skrze růst cen krmiv, který se následně přenese do cen masa a mléčných výrobků. K tomu je třeba připočíst i ceny plynu a elektřiny, které v posledních týdnech v návaznosti na novou eskalaci konfliktu na Blízkém východě začaly citelně růst. Cena zemního plynu se již pohybuje kolem 60 EUR/MWh. Procesy, jako je pasterace nebo sušení mléka, jsou přitom energeticky náročné a vyžadují dodávky plynu za rozumnou cenu.
I proto v příštím roce předpokládáme růst cen potravin minimálně kolem 4 %, tedy mírně nad historickým průměrem. Pokud k tomu připočteme dražší energie, které letos naopak stále zlevňují, a přetrvávající zvýšenou inflaci ve službách, dostáváme se na začátku příštího roku k celkové inflaci v pásmu 3–4 %. Možná i proto finanční trhy současnou nízkou inflaci v zásadě přehlížejí a poslední eskalace napětí na Blízkém východě je vedla ke zvýšení sázek na další růst úrokových sazeb.
TRHY
Koruna
Česká koruna se drží v blízkosti 24,20 bez sebemenších nových impulsů k obchodování. Silný dolar a drahá ropa ji berou vítr z plachet, na druhé straně ovšem ne natolik, aby se dostala do výraznější defenzivy. Hlavní událostí tohoto týdne pro ni bude čtvrteční zasedání ECB.
Eurodolar
Ropný trh se ocitá ve velmi choulostivé situaci, která může mít potenciálně významné dopady i na ostatní finanční trhy, včetně trhu eurodolarového. Problém, jak dostat ropu z Perského zálivu na světové trhy, se totiž posouvá do zcela jiné roviny. Húsiové podporovaní Íránem se rozhodli zablokovat průliv Báb al-Mandab, vstupní bránu z Rudého moře, kterou Saúdská Arábie využívá k přepravě ropy do světových oceánů.
Podle posledních zpráv již několik tankerů bylo nuceno změnit kurz, protože rejdaři nepovažují plavbu touto úžinou za dostatečně bezpečnou. Ceny ropy proto logicky rostou. Ropa Brent se dnes ráno obchodovala již nad 92 USD za barel. To vytváří tlak na oslabení eura vůči dolaru. Kurz EUR/USD se zatím drží nad hladinou 1,14, avšak pokud by ceny ropy zamířily směrem ke 100 USD za barel, je velmi pravděpodobné, že by se dostal pod tuto úroveň.
Forint
Maďarská centrální banka v souladu s očekáváním včera snížila svou základní úrokovou sazbu z 6,0 % na 5,75 % a vyslala poměrně jasný signál, že uvolňování měnové politiky bude během léta pokračovat. MNB to ve svém komentáři dokonce konkretizovala tím, že o dalším snížení sazeb rozhodne zářijová inflační zpráva. To by mělo implikovat, že na srpnovém zasedání ke snížení sazeb ještě nedojde. Forint v reakci na rozhodnutí MNB nepatrně oslabil.
Po včerejším růst na Wall Street (index SP500 ++0,9 %) nyní zámořské futures kontrakty ztrácí -0,3 %. Evropa sice včera nakonec uzavírala také v kladných úrovních, ale se skromnějšími zisky. Středeční ráno lze dle indikací čekat v regionu opět nevýrazné. Investoři sledují vývoj na komoditních trzích, cena ropy Brent se obchoduje nad 92 USD za barel (+2 %). Na mírové rozhovory USA s Íránem to zatím nevypadá. Růst cen ropy tak může znovu rozdmýchat obavy z inflace. Zlato získalo +1,5 % a obchoduje se na nejvyšší úrovní za 2 týdny, když mu pomáhá růst napětí na Blízkém východě. Dnes po zavření trhu budou reportovat firmy Tesla a Alphabet. Zisky společnosti Alphabet budou důležité pro měření nálady na trhu. Pozornost se bude upírat také na farmaceutické společnosti poté, co Trump oznámil plány na zavedení 100 % cla na generické léky do USA. Banco Santander vykázala zisk nad odhady. Praha včera rostla, dařilo se Erste i CSG. Na maximech, kde se obchodoval před dividendou se zvedl ČEZ. Vzhledem k vyšším cenám komodit by se ale mohli postupně na bankách objevovat prodejci.
THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS
SEATTLE--(BUSINESS WIRE)--Amazon Business reaches $60 billion in annualized gross sales and 11 million customers, transforming how organizations of all sizes buy and save.
WAYNE, Pa.--(BUSINESS WIRE)--Cornelis, a leading provider of high-performance networking solutions, unveiled a new reference architecture that pairs its CN6000 SuperNIC with AMD 6th Gen EPYC™ processors and AMD Instinct™ MI400 series GPUs. Designed for disaggregated AI inference, large-scale training, and HPC simulation, the architecture provides infrastructure operators with a blueprint for building high-performance systems on an integrated compute and networking platform.Cornelis plans to deta.
Hydro’s adjusted EBITDA for the second quarter of 2026 was NOK 8,923 million, up from NOK 7,790 million in the same quarter last year. Higher aluminium prices and product premiums contributed positively, together with improved earnings in the recycling business. Lower energy production due to hydrology and adverse effects from a stronger NOK contributed negatively. Hydro delivered strong profitability in the quarter, with adjusted earnings per share increasing from NOK 1.7 in the second quarter 2025 to NOK 2.2 in the second quarter 2026. Free cash flow was NOK 4 billion, with strong adjusted EBITDA partially offset by investments and tax payments. The twelve month adjusted RoaCE ended at 10.9 percent.
Slovalco 75,000 tonnes restart announced on July 1 Realized all-in metal prices up 14 percent from first quarter All-time high casthouse production in Norway, upstream operational performance at high level Recycling results strengthening, adjusted EBITDA NOK 0.9 billion Power sourcing continuing, further 5 TWh sourced in second quarter On July 1, the planned restart of the Slovalco smelter was announced, following an agreement on long-term framework conditions with the Slovak government, including indirect carbon cost compensation. The smelter will restart 75,000 tonnes of capacity during the second half of 2026.
“This quarter reflects both Hydro's operational strength and the opportunities for European industry. Alongside strong financial results driven by solid operational performance and supportive markets, the agreement on a framework to restart Slovalco is an important step toward rebuilding European aluminium capacity. It also demonstrates that competitive energy and predictable framework conditions unlock investments and strengthen Europe's industrial resilience,” says Eivind Kallevik, President and CEO of Hydro.
The second quarter demonstrated continued strong operational performance across Hydro’s upstream businesses. At Alunorte, the refinery productivity increased year on year. In Aluminium Metal, the ramp up of previously curtailed capacity at the Norwegian smelters continued through the quarter, contributing to higher production volumes compared to the same period last year and reinforcing Hydro’s position as a reliable supplier to the European market.
Recycling continued to deliver strong results during the quarter, particularly in North America, where favorable market conditions and robust value added product premiums, supported margins and volumes. Adjusted EBITDA from the recycling operation was over NOK 900 million in the quarter. The continued performance highlights the strength of Hydro’s integrated and increasingly circular business model.
To source competitively priced renewable energy for the aluminium smelters remains a key priority for Hydro. In early July, a 10 year agreement was signed with Eviny, covering 0.5 TWh annually for the period 2031 to 2040. With the latest contract, Hydro has covered 85 percent of its total sourcing need in Norway in the 2030s. However, further development of renewable power is needed to support Hydro’s long-term growth and development plans.
“Hydro has secured a strong power position in Norway well into the next decade. At the same time, Europe needs significantly more renewable power generation if industries like aluminium are to remain competitive and continue investing for the future,” says Kallevik.
Hydro also continued to shape the market for low-carbon and recycled aluminium. During the quarter, Hydro entered a five year supply agreement with Nexans for approximately 85,000 tonnes of low-carbon aluminium wire rod. The agreement supports Europe's growing demand for electricity infrastructure, while strengthening Hydro's position in value added low-carbon aluminium. It also aligns with the recent expansion of wire rod capacity at Karmøy, supporting long-term growth opportunities driven by the energy transition
Results and market development per business area
Adjusted EBITDA for Bauxite & Alumina decreased compared to the second quarter of last year, to NOK 522 million from NOK 1,521 million, primarily due to lower alumina prices and a stronger BRL against the USD, partially offset by higher sales volumes and improved bauxite quality.
PAX traded in a narrow range between USD 303 and USD 330 per mt in the second quarter 2026, reflecting Chinese alumina price trends. Despite lower alumina production at certain refineries in Indonesia and Australia because of raw material supply challenges, the World ex-China alumina market was oversupplied in the quarter. China's alumina market was essentially balanced in the quarter with higher alumina imports offset by lower production because of some production disruptions. Chinese alumina prices were close to the marginal cash cost of production. Approximately half of China’s alumina production depends on bauxite imported from Guinea. The government of Guinea is considering restricting annual bauxite exports volume, but no formal announcement has been made.
Adjusted EBITDA for Energy decreased in the second quarter compared to the same period last year, to NOK 499 million from NOK 1,069 million. The decrease is mainly due to lower production and a loss on price area differences compared to a gain in the same period last year.
Average Nordic power prices in the second quarter of 2026 decreased compared to the previous quarter, but increased compared to the same quarter last year. The decrease from the previous quarter was mainly driven by lower seasonal demand and higher hydro power production following the melting season. Price area differences between the south and north of the Nordic market were above the previous quarter and below the same period last year.
The Nordic hydrological balance at the end of the quarter was 15 TWh below normal, compared to 21 TWh below normal at the end of last quarter and 10 TWh above normal at the same time last year. Norwegian hydropower reservoirs were around 61.9 percent of full capacity at the end of the quarter, which is below the normal for this time of year of 67.9 percent. The distribution was uneven, with lower than normal levels in the south of Norway and higher than normal levels in the north.
Adjusted EBITDA for Aluminium Metal increased in the second quarter of 2026 compared to the second quarter of 2025, to NOK 6,421 million from NOK 2,423 million, due to higher all-in metal prices and lower alumina cost, partly offset by lower sales volume, higher energy and carbon cost, and weaker USD to NOK. Global primary aluminium consumption was slightly higher compared to the second quarter of 2025, driven by a 2.2 percent increase in China. Primary consumption in the World ex-China is estimated to be down compared to the second quarter of 2025. The three month aluminium price decreased towards the end of the second quarter of 2026, starting the quarter at USD 3,532 per mt and ending at USD 3,086 per mt. The U.S. and Iran ceasefire, and subsequently partly opening of the Straight of Hormuz has led to an easing of supply concerns for aluminium globally. More metal has been shipped out of the Middle East and smelter production is recovering.
Adjusted EBITDA for Metal Markets decreased in the second quarter of 2026 compared to the same period last year, to NOK 32 million from NOK 276 million, due to lower results from sourcing and trading activities, partly offset by higher results from recyclers and positive inventory valuation and currency effects.
Adjusted EBITDA for Extrusions increased in the second quarter of 2026 compared to the same quarter last year, to NOK 1,463 million from NOK 1,260 million, driven by higher recycling margins in combination with lower fixed cost partly offset by reduced sales volume.
European extrusion demand is estimated to have increased slightly by 0.4 percent in the second quarter of 2026 compared to the same quarter last year, following a weaker first quarter. Demand in the building & construction and industrial segments showed modest growth in the quarter. Automotive demand remained positive in the first half of the year, supported by continued growth in battery electric vehicle production, while non-automotive transport demand remained subdued.
North American extrusion demand is estimated to have been flat in the second quarter of 2026 compared to the same quarter last year, following a weaker first quarter. Demand in the electrical segment remained solid during the quarter, while activity in the commercial transport segment improved towards the end of the period as price levels moderated. Automotive demand remained weak due to continued headwinds in electric vehicle production.
Other key financials
Compared to the first quarter of 2026, Hydro’s adjusted EBITDA increased to NOK 8,923 million from NOK 8,668 million, mainly due to higher all-in metal prices, improved Extrusions volumes and strong recycling margins in the second quarter of the year. This was partially offset by lower Energy results due to lower power production and losses on price area differences, higher fixed cost in Bauxite & Alumina and negative currency effects in Aluminium Metal.
Net income (loss) amounted to NOK 5,965 million in the second quarter of 2026. Net income (loss) included unrealized derivative gains, mainly on LME related contracts of NOK 3,088 million, rationalization charges and closure costs of NOK 233 million, impairment charges in equity accounted investments of NOK 104 million, and impairment charges on fixed assets of NOK 337 million. The tax effect on these adjustments reflected a standardized tax rate for taxable gains and tax deductible losses. Adjusted net income (loss) for the first quarter ended at NOK 4,601 million.
Hydro’s net debt increased from NOK 12.9 billion to NOK 16.3 billion during the second quarter of 2026. The net debt increase was mainly due to dividends paid, investments and other operating cash flow more than offsetting the EBITDA contribution.
Adjusted net debt increased from NOK 21.6 billion to NOK 22.8 billion, mainly driven by the increase in net debt, partly offset by lower hedging collateral.
Reported earnings before financial items and tax (EBIT), and net income include effects that are disclosed in the quarterly report. Adjustments to EBITDA, EBIT, and net income (loss) are defined and described as part of the alternative performance measures (APM) section in the quarterly report.
The information was submitted for publication from Hydro Investor Relations and the contact persons set out above. Certain statements included in this announcement contain forward-looking information, including, without limitation, information relating to (a) forecasts, projections and estimates, (b) statements of Hydro management concerning plans, objectives and strategies, such as planned expansions, investments, divestments, curtailments or other projects, (c) targeted production volumes and costs, capacities or rates, start-up costs, cost reductions and profit objectives, (d) various expectations about future developments in Hydro's markets, particularly prices, supply and demand and competition, (e) results of operations, (f) margins, (g) growth rates, (h) risk management, and (i) qualified statements such as "expected", "scheduled", "targeted", "planned", "proposed", "intended" or similar. Although we believe that the expectations reflected in such forward-looking statements are reasonable, these forward-looking statements are based on a number of assumptions and forecasts that, by their nature, involve risk and uncertainty.
Various factors could cause our actual results to differ materially from those projected in a forward-looking statement or affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to: our continued ability to reposition and restructure our upstream and downstream businesses; changes in availability and cost of energy and raw materials; global supply and demand for aluminium and aluminium products; world economic growth, including rates of inflation and industrial production; changes in the relative value of currencies and the value of commodity contracts; trends in Hydro's key markets and competition; and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Except where required by law, Hydro disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
NHY presentation Q2 2026 NHY Second Quarter Report 2026
Nike will shift online sales to its official website and app, as well as its flagship stores on e-commerce platforms Tmall, JD.com and Douyin from January.
DALLAS & NEW YORK & ABU DHABI--(BUSINESS WIRE)--The Artificial Intelligence Infrastructure Partnership (“AIP”), MGX, and BlackRock's Global Infrastructure Partners (“GIP”) (collectively, the “Consortium”), today successfully completed their previously announced acquisition of 100% of the equity in Aligned Data Centers (“Aligned” or the “Company”) from private infrastructure funds managed by Macquarie Asset Management and its co-invest partners. The transaction, which represents Aligned's enterp.
V Česku vzbudily pozornost výroky premiéra Andreje Babiše o možné cukrové dani, která by mohla ovlivnit akcie Kofoly. Na globální scéně pokračuje napětí mezi USA a Íránem, které podporuje ceny ropy a udržuje pozornost na klíčových přepravních trasách na Blízkém východě.
Článek se odemkne 22.07.2026 9:50
Pokračování článku je dostupné jen klientům placených služeb Patria Plus / Investor Plus případně uživatelům platformy Patria Direct. Pokud jste klientem těchto služeb, potom je nutné se Přihlásit.
V rámci placeného informačního servisu získáte přístup ke kompletnímu zpravodajství www.patria.cz bez jakýchkoliv omezení. Veškeré zprávy, komentáře a horké zprávy jsou zobrazovány terminálovou metodou (bez nutnosti obnovovat stránku) bez zpoždění a v plné verzi.
Nejen zpravodajství, ale i další služby získáte v Patria Plus / Investor Plus - sms a e-mailové zpravodajství, data z finančních trhů v reálném čase, kompletní analytický servis, rozsáhlé databáze časových řad ke stažení, prognózy vývoje a valuace, ekonomické fundamenty, nástroje a kalkulátory... více
Námi sledované indexy v asijsko-pacifickém regionu se obchodují smíšeně. Zajímavou seanci nabídla Jižní Korea, která v úvodu posilovala o více než 6 %, aby následně zisky smazala a aktuálně rostla pouze o 0,74 %. Extrémní volatilita na polovodičích tak nadále pokračuje, přičemž pozornost se nyní přesouvá k hospodářským výsledkům významných globálních technologických společností. Dnes po uzavření trhů mají své výsledky zveřejnit společnosti Alphabet a Tesla, po nichž bude zítra (také po trhu) následovat Intel.
Výrobce paměťových čipů SK Hynix (aktuálně +0,0 %, v průběhu seance však přidával až +9,3 %) uvedl, že nemá v plánu získat výrobní závody Intelu v Ohiu poté, co média dříve informovala, že vyjednává o koupi čipového areálu.
Japonský Nikkei 225 -0,18 % na 66115,6 b.
Hongkongský Hang Seng -1,26 % na 24814,67 b.
Čínský Shanghai Composite -0,1 % na 3860,423 b.
Jihokorejský Kospi +0,74 % na 6797,7 b.
Australský S&P/ASX 200 +0,34 % na 8823 b.
A container ship, CMA CGM Eiffel, is seen at the port in Dakar, Senegal, February 11, 2025. REUTERS/Zohra Bensemra Purchase Licensing Rights, opens new tab
PARIS, July 22 (Reuters) - CMA CGM will impose an emergency fuel surcharge following the renewed escalation of hostilities in the Strait of Hormuz effective August 1, the French shipping firm said in a notice posted on its website.
"Following the renewed escalation of hostilities in the Strait of Hormuz over the past days, fuel prices have surged sharply again, reversing the easing observed in recent weeks. As a result, bunker costs have significantly increased across all regions and trades, impacting the overall cost of ocean transportation," the firm said.
The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.
The surcharge, which will range from $65 to $165 per container, will be in place until further notice. The notice was dated on Tuesday but was sent in an email to reporters on Wednesday.
Reporting by Gus Trompiz; Editing by Makini Brice and
Our Standards: The Thomson Reuters Trust Principles., opens new tab
FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The primary endpoint results at Week 48 showed that the investigational once-weekly oral single-tablet HIV treatment regimen of islatravir 2 mg/lenacap.
BOX (NYSE:BOX – Get Free Report) and StoneCo (NASDAQ:STNE – Get Free Report) are both mid-cap computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.
Profitability This table compares BOX and StoneCo’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets BOX 10.35% -24.19% 4.66% StoneCo 23.82% 21.05% 4.17% Institutional and Insider Ownership 86.7% of BOX shares are owned by institutional investors. Comparatively, 73.2% of StoneCo shares are owned by institutional investors. 4.0% of BOX shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility & Risk BOX has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, StoneCo has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500.
Valuation and Earnings This table compares BOX and StoneCo”s revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BOX $1.18 billion 3.53 $115.38 million $0.65 46.16 StoneCo $13.62 billion 0.21 $425.73 million $2.50 4.50 StoneCo has higher revenue and earnings than BOX. StoneCo is trading at a lower price-to-earnings ratio than BOX, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings This is a breakdown of current ratings and recommmendations for BOX and StoneCo, as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BOX 1 5 3 0 2.22 StoneCo 0 5 4 0 2.44 BOX currently has a consensus price target of $35.33, suggesting a potential upside of 17.77%. StoneCo has a consensus price target of $14.92, suggesting a potential upside of 32.47%. Given StoneCo’s stronger consensus rating and higher probable upside, analysts clearly believe StoneCo is more favorable than BOX.
Summary StoneCo beats BOX on 9 of the 14 factors compared between the two stocks.
About BOX (Get Free Report)
Box, Inc. engages in the provision of an enterprise content platform that enables organizations to securely manage enterprise content while allowing easy, secure access and sharing of this content from anywhere, on any device. Its products include cloud content management, IT and admin controls, Box Governance, Box Zones, Box Relay, Box Shuttle, and Box KeySafe. The company was founded by Aaron Levie, Dylan Smith, Jeff Queisser, and Sam Ghods in March 2005 and is headquartered in Redwood City, CA.
About StoneCo (Get Free Report)
StoneCo Ltd. provides financial technology and software solutions to merchants and integrated partners to conduct electronic commerce across in-store, online, and mobile channels in Brazil. It distributes its solutions, principally through proprietary Stone Hubs, which offer hyper-local sales and services; and sells solutions to brick-and-mortar and digital merchants through sales team. The company served small-and-medium-sized businesses; and marketplaces, e-commerce platforms, and integrated software vendors. StoneCo Ltd. was founded in 2000 and is headquartered in George Town, the Cayman Islands.
Receive News & Ratings for BOX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BOX and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAnalysts Set Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Target Price at $38.33
NEXT HEADLINE »Analyzing American Resources (NASDAQ:AREC) and Western Uranium (OTCMKTS:WSTRF)
Tuesday was the day the memory trade turned back around. Micron Technology (MU +12.26%), Western Digital (WDC +12.60%), and Sandisk (SNDK +14.33%) rose 12%, 12.5%, and 14.3%, respectively, in Tuesday's session. It was a violent reversal for three stocks that entered the day down 31%, 39%, and 41% from their 52-week highs.
The biggest catalyst was a single forecast. In a Monday note, Morgan Stanley reportedly told clients it expects memory prices to rise at least 25% from the second quarter to the third, with artificial intelligence (AI) data-center demand keeping supply tight. The firm's checks reportedly found no sign the shortage is easing, and it said shortages could grow even more severe in 2027 and 2028. The group started climbing on the note Monday. On Tuesday, the buying turned into a surge.
For a group of stocks that had spent two weeks selling off on fears the memory boom was ending, that was the whole argument. If prices are still rising, the boom isn't over. Here's what the forecast means for each of the three.
Image source: Micron.
Micron has the broadest exposure Micron is the biggest of the three and the most watched. The company sells both major categories of memory chips (DRAM and NAND flash), plus the high-bandwidth memory that AI accelerators depend on. So a rising price forecast touches nearly everything it ships.
Its latest results show what that leverage already looks like. Revenue for Micron's fiscal third quarter (the period ended May 28) more than quadrupled year over year to $41.5 billion, the company's fifth consecutive quarterly revenue record. Net income came in at $28.2 billion. And operating cash flow more than doubled sequentially, to $25.4 billion from $11.9 billion the prior quarter.
Today's Change
(
12.26
%) $
106.13
Current Price
$
971.59
"Micron's record fiscal Q3 financial results and even stronger outlook for Q4 reflect the strategic value of memory in the AI era," CEO Sanjay Mehrotra said in the company's June earnings release.
Even after Tuesday's move, the stock trades at about 20 times earnings, a multiple that says investors still doubt numbers like these can last.
Western Digital rode along Western Digital is the odd one out: it doesn't sell memory chips at all. The company makes hard disk drives, the slower, cheaper storage tier that data centers deploy in enormous volumes. Its leverage to a memory-price forecast is indirect.
Its own supply picture, however, is just as tight. Revenue for its fiscal third quarter (the period ended April 3) rose 45% year over year to $3.3 billion, and guidance calls for 36% to 44% year-over-year growth in the fiscal fourth quarter.
Today's Change
(
12.60
%) $
61.43
Current Price
$
548.85
"The demand drivers are clear: Virtually every AI workload, from training, inference, agentic AI to physical AI, creates data that is stored persistently and cost-efficiently on HDDs," Western Digital CEO Irving Tan said in the company's April earnings release.
When every tier of data-center storage is scarce at once, the market trades the group as one bet on AI's appetite for capacity. Tuesday showed as much.
Sandisk is the purest play Sandisk sells NAND flash, the exact product whose price Morgan Stanley expects to jump. That arguably makes it the most direct way to own the forecast.
Its results show what rising NAND prices do to a focused producer. Sandisk's fiscal third-quarter revenue rose 251% year over year to $5.95 billion, and non-GAAP (adjusted) gross margin reached 78.4%, up more than 55 percentage points from a year earlier. When the price of a company's core product surges, most of the increase lands in gross profit.
Today's Change
(
14.33
%) $
199.31
Current Price
$
1,590.26
The company is also locking in demand, signing five multiyear supply agreements under a new business model built on firm customer commitments. And its guidance calls for $7.75 billion to $8.25 billion of revenue in its just-ended fiscal fourth quarter, or roughly 34% sequential growth at the midpoint.
One forecast, three different bets So which of the three has the most direct leverage to rising memory prices? Arguably, Sandisk, whose entire business is the product in question. Micron is close behind, with broader exposure across DRAM, NAND, and high-bandwidth memory. Western Digital benefits at one remove, through the same data-center scramble that is straining storage supply of every kind.
Of course, a forecast is still just a forecast, and memory remains the most cyclical corner of the chip industry. The same operating leverage that multiplies profits on the way up works in reverse when prices roll over. The roughly 30% to 40% drawdowns these stocks carried into Tuesday existed precisely because investors understand this risk.
Ultimately, I wouldn't chase Tuesday's move. If Morgan Stanley is right about the third quarter, these companies' results will do the talking soon enough. And if it's wrong, this group has demonstrated in recent weeks just how fast it can reprice in either direction.
AMC Entertainment (NYSE:AMC) reported what executives described as the strongest quarterly results in the company’s 106-year history, with record revenue, record adjusted EBITDA and sharply improved free cash flow in the second quarter of 2026.
Chairman and Chief Executive Officer Adam Aron said more than 71 million guests visited AMC and Odeon theaters worldwide during the April-to-June period, up 13.5% from a year earlier. Total revenue increased 14.2% year over year to approximately $1.6 billion, while adjusted EBITDA rose 70% to $321.4 million, surpassing $300 million in a quarter for the first time, according to the company.
“In AMC’s entire 106-year history, there has never been a quarter like this one,” Aron said on the company’s earnings call. He added that both revenue and adjusted EBITDA exceeded Wall Street expectations.
Free cash flow for the quarter was $190.1 million, and AMC ended June with $778 million of cash on hand, excluding restricted cash.
Box Office Strength Boosts Results AMC executives pointed to a stronger theatrical slate as a key driver of the quarter. Aron said the domestic industry box office reached $2.99 billion in the second quarter, the highest second quarter in seven years and, based on his review of the data, the fifth-best quarter in the past 50 years.
Six films from Universal, Lionsgate, A24 and Disney each opened domestically to more than $75 million during the period, Aron said. AMC’s domestic ticket revenue rose 11.4%, ahead of the 10.7% increase in the overall domestic box office, while European attendance increased 18% year over year.
Chief Financial Officer Sean Goodman said AMC’s performance was broad-based across its global circuit. In the United States, adjusted EBITDA increased 57.5% to $285.6 million. In Europe, adjusted EBITDA increased 337% to $35.8 million. Goodman noted that international revenue and EBITDA benefited by about 2% from European currency appreciation against the U.S. dollar.
Food and beverage and merchandise sales increased 15.3% globally, while “other revenues” increased 16.1%, Aron said. Goodman added that food and beverage revenue per patron and total revenue per patron reached all-time highs in both the domestic and international businesses.
Margins Improve as Costs Remain Contained AMC’s adjusted EBITDA margin rose to 20.1% in the second quarter from 13.6% a year earlier. Goodman said roughly $200 million of incremental revenue generated $131.9 million of additional adjusted EBITDA, representing about 66% flow-through.
Aron attributed the margin expansion to rising revenue and cost controls across AMC’s theaters and corporate operations. In response to an analyst question, Aron said the company may not repeat the same level of expense containment every quarter, but management intends to remain focused on keeping costs down.
“We’re going to be maniacal in continuing to try to keep our costs down,” Aron said.
Goodman said second-quarter 2026 general and administrative expenses benefited from an approximately $5.5 million credit related to insurance recoveries.
Balance Sheet Actions Reduce Debt and Interest Expense Executives also highlighted progress on AMC’s balance sheet. Aron said the company has $1.7 billion less debt than it had at the end of 2020 and does not expect significant debt maturities before 2029.
Goodman said AMC refinanced $400 million of debt due in 2027, extending the maturity by four years. The company also eliminated approximately $155.8 million of exchangeable debt due in 2030 through conversion into equity.
AMC completed a $150 million at-the-market equity offering, raising more than $85 million of gross proceeds during the second quarter, Goodman said. The company also recently completed a $200 million registered direct equity offering with several institutional investors. Following that transaction, AMC exercised its right to redeem the remaining $125.5 million of 6.8% senior subordinated notes due in 2027, with redemption scheduled for July 24, 2026.
Goodman said the refinancing and repayment actions reduced go-forward annual cash interest expense by approximately $16 million. He added that lower leverage ratios are expected to trigger interest-rate reductions on about 75% of AMC’s debt, lowering annual interest expense by approximately $51 million.
In response to a question about leverage, Goodman said AMC ultimately would like to reach around a three-times leverage level, though he acknowledged the company is not there yet. He said leverage has improved from a double-digit level to less than 6.5 times.
Premium Formats, Loyalty Programs Remain Strategic Focus AMC executives said loyalty programs and premium formats remain central to the company’s strategy. Aron said more than 40 million U.S. households have participated in AMC Stubs, and Stubs members accounted for just over 50% of AMC’s U.S. guest count in the second quarter.
AMC’s A-List subscription program ended the quarter with more than 1.1 million members, more than double its membership five years earlier, Aron said. A-List members accounted for about 20% of AMC’s U.S. patronage in the quarter.
Goodman said AMC closed seven theaters during the quarter and added six new premium large format auditoriums and 25 new XL auditoriums. Since 2020, AMC has closed 225 locations and opened 66, reducing its global theater count by 159 locations, or about 16% of its circuit. Over the same period, the company has added 77 premium large format auditoriums and 193 XL auditoriums.
Aron said AMC and Odeon now operate about 750 premium or enhanced auditoriums globally, including IMAX, Dolby, iSENSE, PRIME, ScreenX, 4DX and XL screens. He said those auditoriums represent about 8% of AMC’s screen count but generated more than 50% of AMC’s ticket gross for “The Odyssey” over the weekend discussed on the call.
AMC expects 2026 net capital expenditures of $200 million to $235 million. Goodman said the company will remain disciplined and that future capital spending will depend on box office expectations and project-level returns.
Management Expresses Optimism for 2026 Slate Looking ahead, Aron cited the opening of Universal Pictures and Christopher Nolan’s “The Odyssey,” which he said had a media-reported $124 million domestic opening weekend. AMC also said 4.3 million guests attended AMC and Odeon theaters from Thursday to Sunday during that weekend.
Aron said upcoming releases including Sony’s “Spider-Man: Brand New Day,” Warner Bros.’ “Dune: Part Three” and Disney’s “Avengers: Doomsday” support management’s view that 2026 could be the strongest post-pandemic year yet for the domestic and global box office.
Executives said AMC’s annual free cash flow breakeven box office level is currently around $10.4 billion. Aron said the company is “within sight” of being free cash flow positive on a 12-month basis, but is not there yet.
About AMC Entertainment (NYSE:AMC) AMC Entertainment Holdings, Inc operates as a leading movie exhibition company, specializing in the presentation of theatrical motion pictures across a network of multiplex cinemas. The company’s core business activities encompass ticket sales, concession and refreshment services, and the licensing of premium viewing formats. AMC offers a variety of auditorium experiences, including IMAX®, Dolby Cinema™, and Cinemark’s RealD 3D systems, designed to enhance audience engagement through superior sound, visual clarity, and seating comfort.
Originally founded in 1920 with its first theatre in Kansas City, AMC has evolved into one of the largest theater chains in the world.
NEW YORK--(BUSINESS WIRE)---- $REGN #BFA--Regeneron Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA.
Pressure from President Donald Trump to manufacture advanced semiconductors in the U.S. is increasing costs and squeezing margins at TSMC, the world's leading chipmaker.
Following Trump's return to power in 2025, the president has repeatedly threatened tariffs on companies that don't make their products in America.
Since then, TSMC has announced a total of $200 billion in commitments to the country, including last week's unveiling of a $100 billion investment into advanced semiconductor manufacturing and packaging facilities in the U.S.
While buoyed by the AI boom — TSMC's market cap has risen more than 100% in the past 12 months — blockbuster earnings this quarter were hit by overseas expansion, the company said.
TSMC stock.
Gross margin increased ahead of guidance, but that was offset by dilution from overseas fabs, CFO Wendell Huang said on an earnings call. Margins will be further diluted over the next "several years" as overseas fab projects "ramp-up", he added.
"President Trump's leadership is driving companies to invest in American manufacturing," said Commerce Secretary Howard Lutnick in a statement.
"TSMC's announcement of an additional $100 billion investment following our historic deal on trade and investment with Taiwan will create tens of thousands of American jobs and bring advanced semiconductor manufacturing back to America."
While other Asian chipmakers, including SK Hynix, are developing U.S. facilities, TSMC has made by far the largest commitment. Its aggressive U.S. expansion exposes it to higher production costs, creating a potential headwind for margins.
Political pressureTSMC on Thursday reported a 77.4% jump in second-quarter profit year on year, soaring past estimates and marking another record-breaking quarter for the world's largest contract-chipmaker.
It's also expanding aggressively in the U.S., as the company continues to see a "multi-year demand mega trend" from its customers, TSMC's Huang told CNBC.
Political pressure is another key driver of that overseas expansion.
"Trillions of dollars in investments by TSMC and other semiconductor companies are a result of President Trump's trade and economic policy, from a historic trade deal with Taiwan to renegotiated CHIPS program investments," a White House spokesperson told CNBC.
watch now
Building in the U.S. is considerably more expensive.
"Broadly, we estimate TSMC's US chips to cost 20-50% more than those produced in Taiwan, depending on subsidy timing, tax credit recognition and other cost fluctuations," Phelix Lee, senior equity analyst at Morningstar, told CNBC. Lee added he expected customers to bear more of the higher costs of production.
TSMC is set to raise prices for both advanced and mature chip production by up to 10% in 2027, Nikkei reported on Tuesday. TSMC told CNBC it doesn't comment on pricing.
"What helps TSMC is lack of any material competition," Gaurav Gupta, VP analyst at Gartner, told CNBC.
Because of TSMC's dominance in the leading-edge node market, "a large part of the increased costs would have to be absorbed by its clients, who are looking to diversify or have mandates from the U.S government to purchase local chips," Gupta said.
Margins The company forecasts the gross margin dilution from the ramp-up of overseas fabs in the next several years to be 2% to 3% in the early stages, widening to 3% to 4% in the latter stages, Huang said.
"This is a margin difference TSMC can afford because of its very high overall margins," said Gil Luria, head of technology research at D.A. Davidson. TSMC's second-quarter gross margin was 67.7%, up slightly from 66.2% in the first quarter.
While Trump has doubled down on calls for homegrown manufacturing, "customers have increasingly sought geographical diversification after Covid disrupted the global supply chain," said Morningstar's Lee.
"Customers are bracing for geopolitical, logistical, and other disruptions to the supply chain," he added. "We expect made-in-US pressure to persist beyond Trump, although it is less clear how carrot-and-stick will be distributed."
ImmuPharma PLC (AIM:IMM, FRA:25I), the drug discovery company, has appointed Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes treatment Kapiglucagon.
The US group was chosen after a competitive tender, with its Patheon pharma services arm taking on the drug product workstream.
The appointment follows the recent selection of Swiss group Bachem to manufacture the active ingredient, completing the main manufacturing partnerships for the programme.
Kapiglucagon is a prodrug version of glucagon, a hormone that raises blood sugar, designed for use in Type 1 diabetes.
A prodrug is an inactive compound that converts into the active medicine inside the body, an approach used here to get around glucagon's tendency to be poorly soluble and unstable once mixed into a formulation.
ImmuPharma is targeting dual-hormone artificial pancreas systems, devices that deliver both insulin to lower blood sugar and glucagon to raise it, mimicking the function of a healthy pancreas.
The company is evaluating a 505(b)(2) route in the United States, a regulatory pathway that allows developers to lean on existing safety data for an approved drug rather than repeating the full testing programme.
That approach relies on published data for native glucagon and remains subject to confirmation by the Food and Drug Administration.
Sébastien Goudreau, chief scientific officer, said the appointment strengthened the manufacturing and quality foundation of the programme as it moves towards clinical development.
Jennifer Cannon, president of commercial biopharma services at Thermo Fisher, said her team would support ImmuPharma through key development milestones.
The next stage involves preparing an investigational new drug application, the submission required before human testing can begin in the United States.
ImmuPharma has described Kapiglucagon as a strategic opportunity alongside P140, its lead candidate for the autoimmune disease lupus.
The programme is backed by a funding package approved recently and intended to advance the asset over the next two years.
Brings GTF order backlog to more than 8,000 engines
, /PRNewswire/ -- Farnborough International Airshow – Pratt & Whitney, an RTX (NYSE: RTX) business, has received more than 800 GTF engine orders and commitments since the beginning of 2026. Airlines and lessors that have announced orders so far this year include Abra Group, AirAsia, Azorra, Binter, British Airways, Finnair, Jackson Square Aviation, Luxair, Scoot, Tigerair Taiwan and VietJet. In total, more than 14,000 GTF engine orders and commitments have been placed by more than 90 customers worldwide.
"We see strong demand for the GTF engine and continued confidence in the value it delivers to customers," said Rick Deurloo, president of Commercial Engines at Pratt & Whitney. "The GTF Advantage engine will enter into service later this year and will provide up to twice the time on wing, industry-leading fuel efficiency and even more range capability."
The GTF is the most fuel efficient engine for the single aisle market, delivering up to 20% lower fuel consumption and a 75% smaller noise footprint compared to the prior generation of engines. The engine's revolutionary geared architecture will serve as the foundation for next-generation propulsion technologies and is expected to have accumulated more than 300 million hours of flying time by the mid-2030s.
About Pratt & Whitney
Pratt & Whitney, an RTX business, is a world leader in the design, manufacture and service of aircraft engines and auxiliary power units for military, commercial and civil aviation customers. Since 1925, our engineers have pioneered the development of revolutionary aircraft propulsion technologies, and today we support more than 90,000 in-service engines through our global network of maintenance, repair and overhaul facilities.
About RTX
With more than 180,000 global employees, RTX pushes the limits of technology and science to redefine how we connect and protect our world. With industry-leading capabilities, we advance aviation, engineer integrated defense systems for operational success, and develop next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2025 sales of more than $88 billion, is headquartered in Arlington, Virginia.
For questions or to schedule an interview, please contact [email protected]
Collins Aerospace lab completes Clean Aviation SWITCH testing and moves on to LEIA project
, /PRNewswire/ -- Farnborough International Air Show – Collins Aerospace, an RTX (NYSE: RTX) business, has completed integrated lab testing for the European Union's Clean Aviation SWITCH project at The Grid, its advanced electric power systems lab in Rockford, Ill. The tested hybrid-electric powertrain subsystems, which successfully operated with simulated aircraft and engine systems, are now headed to Airbus's laboratories for further aircraft level integration testing, including work on aircraft design, battery interfacing and energy-management systems.
"This is the largest integrated systems test conducted at The Grid since its opening in 2023," said Kristin Smith, vice president of Electric Power Systems at Collins Aerospace. "By combining our technology expertise with deep industry collaboration, we are demonstrating how hybrid-electric systems can significantly reduce fuel consumption for next-generation aircraft."
SWITCH aims to improve engine efficiency for future short- and medium-range aircraft by integrating hybrid-electric systems on a Pratt & Whitney GTF™ engine, including two Collins megawatt class motor generators and controllers. Testing at The Grid was supported by Pratt & Whitney teams who performed powertrain system integration and supplied the hybrid-electric engine controller, and Airbus teams who supplied the interface controller to the aircraft energy-management system. GKN Aerospace delivered the high-voltage wiring system.
Next, The Grid will support the Airbus-led LEIA (Large scalE Integration demonstrator of hybrid electrical Architecture) project, where Collins is technical lead for energy sources. This Clean Aviation demonstrator advances components and aircraft systems for future hybrid-electric short- and medium-range aircraft, including high voltage generation and distribution.
Collins will deliver advanced aircraft electric system technologies, including four scalable electric motor/generators, next-generation electronic controllers, power distribution equipment, and cabin pressure and ventilation control systems to enhance reliability and passenger comfort. The Nördlingen, Germany site will supply solid-state power controllers and power distribution panels to replace mechanical circuit breakers and relays boosting reliability and reducing weight. LEIA testing will occur across several sites, including The Grid, with additional work at Collins' facilities in Toulouse, France; Frankfurt, Germany; Cork, Ireland; Rome, Italy; and Solihull, UK.
According to Pierre Durel, Project Officer at Clean Aviation, "SWITCH & LEIA are essential building blocks to make the hybrid-electric short- and medium-range aircraft become a reality: they show the power of collaboration within Europe and beyond." He adds that Clean Aviation is "very much looking forward to the results of the demonstration tests due to be carried out in 2027."
Both SWITCH and LEIA build on the ongoing collaboration between Collins and several partners across multiple Clean Aviation projects, including HECATE and AWATAR, which advance electrification technologies for future regional and short-and-medium range aircraft. Collins also contributes to Clean Aviation's newest ultra-efficient regional aircraft projects, including OSYRYS and PHARES. MTU Aero Engines coordinates the SWITCH project.
About Collins Aerospace
Collins Aerospace, an RTX business, provides advanced aerospace and defense solutions across avionics, aircraft interiors, aerostructures and engine components, mission systems, and power and control systems. Our global employees are dedicated to delivering innovative technologies to enhance aircraft performance, passenger comfort, operational safety and reliability.
About RTX
With more than 180,000 global employees, we push the limits of technology and science to redefine how we connect and protect our world. With industry-leading capabilities, we advance aviation, engineer integrated defense systems for operational success, and develop next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2025 sales of more than $88 billion, is headquartered in Arlington, Virginia.
About the Clean Aviation Joint Undertaking
The Clean Aviation Joint Undertaking is the European Union's leading research and innovation programme for transforming aviation towards a sustainable and climate-neutral future. It is a successful European public-private partnership between the European Commission through Horizon Europe, the EU research and innovation programme, and the European aeronautics industry. It has a budget of €4.1 billion divided into €1.7 billion in EU funding and no less than €2.4 billion in private funding. The programme's disruptive clean aviation technologies will help reduce the emission footprint of short-medium range and regional aircraft by no less than 30% compared to 2020 state-of-the-art aircraft. Clean Aviation builds on the knowledge and expertise of the Clean Sky programmes (2008-2024).
For questions or to schedule an interview, please contact [email protected].
NEW YORK--(BUSINESS WIRE)--Morgan Stanley Wealth Management today announced the results of its quarterly retail investor pulse survey: Bullishness ticks up. Over three in five (62%) investors are bullish this quarter, up from 56% last quarter, while 66% expect markets to move higher by quarter-end compared to 55% in Q2. Concern for volatility remains pronounced, but eases slightly. Fewer investors expect volatility to rise this quarter, with 61% anticipating an increase compared to 63% last qua.
Broadcom remains essential in global tech, supplying critical chips and enabling hyperscalers to build custom silicon, challenging Nvidia's dominance. The renewed $30 billion, 6-year Apple deal secures AVGO's position in Apple's supply chain, maintaining a ~$5 billion annual revenue stream. AVGO's collaboration with OpenAI on custom AI processors highlights its role as an irreplaceable 'pick and shovel' provider in the AI infrastructure shift.
Bitmine possiede il 4,8% dell'offerta totale di ETH pari a 120,7 milioni
Bitmine ha raggiunto il 96% dell'obiettivo "Alchemy of 5%" in soli 12 mesi
Nell'ultima settimana, Bitmine ha riacquistato 5,5 milioni di azioni ordinarie, autorizzate nell'ambito del programma di riacquisto di azioni da 4 miliardi di dollari comunicato in precedenza
Bitmine è stata aggiunta all'indice Russell 1000 Large-cap il 26 giugno 2026
Le azioni privilegiate di Serie A di Bitmine saranno negoziate sul NYSE con il simbolo BMNP
Bitmine detiene 4.917.189 ETH in staking, pari a 9,2 miliardi di dollari al prezzo di 1.879 dollari per ETH MAVAN (Made in America VAlidator Network) è una delle principali destinazioni di staking Ethereum per BMNR e investitori istituzional
Bitmine possiede 58 milioni di dollari di Eightco (NASDAQ: ORBS), attualmente uno dei pochi titoli quotati in borsa al mondo che offre agli investitori un'esposizione diretta a OpenAI
Bitmine Crypto + totale disponibilità in contanti + "Moonshots" ammontano a 11,5 miliardi di dollari, inclusi 5,78 milioni di token ETH, liquidità totali e titoli negoziabili pari a 385 milioni di dollari, e altre disponibilità in criptovalute
Bitmine continua a essere sostenuta da un gruppo di investitori istituzionali di primario livello, tra cui ARK di Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital e l'investitore privato Thomas "Tom" Lee a sostegno dell'obiettivo di Bitmine di acquisire il 5% di ETH
, /PRNewswire/ -- (NYSE: BMNR) Bitmine Immersion Technologies, Inc. ("Bitmine" o la "Società"), una società attiva nelle reti Bitcoin ed Ethereum e specializzata nell'accumulo di criptovalute per investimenti a lungo termine, ha annunciato oggi che le sue partecipazioni in criptovalute + liquidità totale e titoli negoziabili + "moonshot" ammontano complessivamente a 11,5 miliardi di dollari.
Bitmine Weekly Update
STAKING: BMNR now staking over 4.9 million ETH as of July 19, 2026
ALCHEMY OF 5%: BMNR ranked #187 by 5D avg daily $ volume Alle 20:30 ET del 19 luglio 2026, le partecipazioni in criptovalute della Società comprendono 5.777.468 ETH al prezzo di 1.879 dollari per ETH (NASDAQ: COIN), 207 Bitcoin (BTC), una partecipazione di 180 milioni di dollari in Beast Industries e una di 58 milioni di dollari in Eightco Holdings (NASDAQ: ORBS) ("moonshots"), e una liquidità totale e titoli negoziabili pari a 385 milioni di dollari. Le partecipazioni in ETH di Bitmine rappresentano il 4,8% dell'offerta di ETH (pari a 120,7 milioni di ETH).
"Nell'ultima settimana, Bitmine ha riacquistato circa 5,5 milioni di azioni ordinarie a un prezzo medio di 15,6156 dollari. Riteniamo l'acquisto delle nostre azioni ordinarie come un elemento che incrementa il valore per gli azionisti", ha affermato Thomas "Tom" Lee, Presidente di Bitmine.
Bitmine ha eseguito il riacquisto di 5,5 milioni di azioni ordinarie nell'ambito del programma di riacquisto di azioni da 4 miliardi di dollari autorizzato in precedenza.
"Nell'ultima settimana, abbiamo acquisito 7.430 ETH. Il ritmo ridotto degli acquisti riflette il fatto che Bitmine ha riacquistato 5,5 milioni di azioni ordinarie. Bitmine ha acquistato ETH ogni settimana sin dall'inizio della strategia di tesoreria ETH, il 30 giugno 2025", ha affermato Lee.
Il 16 luglio 2026, Bitmine ha pubblicato l'ultimo messaggio del presidente (link qui) per il mese luglio 2026. Il titolo del messaggio è "ETH è la cura per la Valle perturbante della ricchezza".
All'inizio del 2026, Bitmine ha lanciato MAVAN (Made in American VAlidator Network), la piattaforma di staking di livello istituzionale. Sebbene sia stata originariamente sviluppata per supportare il tesoro Ethereum di Bitmine, MAVAN intende ampliarsi per raggiungere investitori istituzionali, custodi e partner dell'ecosistema alla ricerca della migliore infrastruttura di staking. Una parte degli ETH di Bitmine è già in staking sulla piattaforma MAVAN.
Al 19 luglio 2026, il totale di ETH in staking su Bitmine ammonta a 4.917.189 (9,2 miliardi di dollari al prezzo di 1.879 dollari per ETH). "Bitmine ha messo in staking più ETH di qualsiasi altra entità al mondo. Su larga scala (quando l'ETH di Bitmine è interamente messo in staking da MAVAN e dai suoi partner di staking), il rendimento previsto dallo staking di ETH è di 290 milioni di dollari all'anno (utilizzando un rendimento BMNR a 7 giorni del 2,67%)", ha dichiarato Lee.
"I ricavi annuali derivanti dallo staking sono attualmente pari a 247 milioni di dollari. E questi 4,9 milioni di ETH rappresentano oltre l'85% dei 5,78 milioni di ETH detenuti da Bitmine. Le operazioni di staking di Bitmine hanno generato un rendimento su 7 giorni del 2,67% (su base annua)", ha proseguito Lee.
La holding in criptovalute Bitmine è al 1° posto delle tesorerie Ethereum e al 2° posto delle tesorerie globali, dietro a Strategy Inc., che secondo quanto riferito possiede 843.775 BTC per un valore di circa 55 miliardi di dollari. Bitmine si conferma la più grande tesoreria di ETH al mondo.
Bitmine è uno dei titoli più scambiati negli Stati Uniti. Secondo i dati di Fundstrat, il titolo ha registrato un volume medio giornaliero di negoziazioni pari a 579 milioni di dollari (media a 5 giorni, al 17 luglio 2026), classificandosi al 187° posto negli Stati Uniti, dietro AirBnB (186° posto) e davanti a Fastenal (188° posto) tra 5.704 titoli quotati negli Stati Uniti (statista.com e ricerca di Fundstrat).
Il management di Bitmine ritiene che il GENIUS Act e il Project Crypto della Securities and Exchange Commission ("SEC") rappresentino, per i servizi finanziari nel 2025, una trasformazione pari a quella determinata dall'azione intrapresa dagli Stati Uniti il 15 agosto 1971, che pose fine al sistema di Bretton Woods e al gold standard del dollaro statunitense 54 anni fa. Questo evento del 1971 fu il catalizzatore della modernizzazione di Wall Street, dando vita agli iconici titani di Wall Street e alle infrastrutture finanziarie e di pagamento odierne. Questi investimenti si sono rivelati più efficaci dell'oro.
Il messaggio del Presidente è disponibile qui:
https://www.Bitminetech.io/chairmans-message
La presentazione degli utili dell'intero esercizio 2025 e la presentazione aziendale sono disponibili qui: https://Bitminetech.io/investor-relations/
Per tutti gli aggiornamenti, è possibile registrarsi all'indirizzo: https://Bitminetech.io/contact-us/
Informazioni su Bitmine
Bitmine (NYSE: BMNR) è un miner di Bitcoin con attività negli Stati Uniti. La società sta utilizzando il proprio capitale in eccesso per diventare la principale società di tesoreria di Ethereum al mondo, implementando un'innovativa strategia di asset digitali per investitori istituzionali e operatori del mercato pubblico. Guidata dalla sua filosofia della "alchimia del 5%", la Società è impegnata a utilizzare ETH come principale asset di riserva di tesoreria, sfruttando attività native a livello di protocollo, tra cui lo staking e i meccanismi di finanza decentralizzata. Nel 2026, la società ha lanciato MAVAN (Made-in America VAlidator Network), un'infrastruttura di staking dedicata per gli asset Bitmine.
Per ulteriori dettagli, seguiteci su X:
https://x.com/bitmnr
https://x.com/fundstrat
Dichiarazioni previsionali
Il presente comunicato stampa contiene dichiarazioni che costituiscono "dichiarazioni previsionali" ai sensi del Private Securities Litigation Reform Act del 1995. Le dichiarazioni contenute nel presente comunicato stampa che non sono puramente storiche sono dichiarazioni previsionali che comportano rischi e incertezze. Queste dichiarazioni previsionali possono essere identificate da termini quali "prevede", "progetta", "progettato", "intende", "crede", "anticipa", "stima" ed espressioni simili. Il presente documento contiene dichiarazioni previsionali riguardanti, in particolare: (i) gli obiettivi della Società in merito all'acquisizione di ETH, tra cui l'iniziativa "Alchemy of 5%" e la dichiarazione, secondo cui Bitmine ha raggiunto il 96% di tale obiettivo; (ii) la strategia della Società di accumulo di asset digitali e le operazioni di staking, incluso il dato relativo ai 4.917.189 ETH in staking detenuti da Bitmine (pari a 9,2 miliardi di dollari), le ricompense annualizzate previste per lo staking di ETH (circa 290 milioni di dollari, quando MAVAN e i partner di staking hanno totalmente in staking l'ETH di Bitmine) e gli attuali ricavi annualizzati previsti dallo staking (circa 247 milioni di dollari); (iii) l'espansione prevista da MAVAN per servire investitori istituzionali, custodi e partner dell'ecosistema che cercano la migliore infrastruttura di staking; (iv) il costante impegno della Società nell'acquisizione settimanale di ETH nell'ambito della propria strategia di tesoreria in ETH; (v) la convinzione del management che il GENIUS Act e il SEC Project Crypto abbiano per i servizi finanziari una portata trasformativa analoga a quella del provvedimento statunitense del 15 agosto 1971 che pose termine a Bretton Woods e al gold standard del dollaro USA; (vi) le aspettative relative al programma di riacquisto di azioni da 4 miliardi di dollari e al valore incrementale per gli azionisti; (vii) le dichiarazioni, secondo cui l'investimento della Società in Eightco Holdings offre un'esposizione indiretta a OpenAI; e (viii) la crescita e il progresso futuri della strategia di tesoreria Ethereum della Società. Nel valutare tali dichiarazioni previsionali, occorre considerare vari fattori, tra cui: la capacità di Bitmine di stare al passo con le nuove tecnologie e le mutevoli esigenze del mercato; la capacità di Bitmine di finanziare la propria attività attuale, le operazioni di tesoreria di Ethereum, le operazioni di riacquisto delle azioni, e le attività future proposte; il contesto competitivo in cui opera Bitmine; le condizioni di mercato che influenzano il prezzo di negoziazione delle azioni ordinarie e delle azioni privilegiate di Serie A della Società; gli sviluppi normativi che riguardano gli asset digitali, tra cui l'emanazione e l'attuazione definitiva della legislazione in corso e delle iniziative della SEC; la volatilità e l'imprevedibilità dei prezzi degli asset digitali; le prestazioni, l'affidabilità e la sicurezza delle operazioni di staking della Società; i rischi riguardanti i sistemi di IA e il relativo impatto sui mercati delle criptovalute; e il valore futuro di Bitcoin ed Ethereum. Le prestazioni future e i risultati futuri effettivi potrebbero differire notevolmente da quelli espressi nelle dichiarazioni previsionali. Le dichiarazioni previsionali sono soggette a numerose condizioni, molte delle quali esulano dal controllo di Bitmine, comprese quelle indicate nella sezione "Fattori di rischio" del modulo 10-K di Bitmine depositato presso la SEC il 21 novembre 2025, nonché in tutti gli altri documenti depositati presso la SEC, modificati o aggiornati di volta in volta. Le copie dei documenti depositati da Bitmine presso la SEC sono disponibili sul sito web della SEC all'indirizzo www.sec.gov. Bitmine non si assume alcun obbligo di aggiornare tali dichiarazioni in seguito a revisioni o modifiche successive alla data del presente comunicato, salvo quanto previsto dalla legge.
Vitro Diagnostics (OTCMKTS:VODG – Get Free Report) and Biogen (NASDAQ:BIIB – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
Profitability This table compares Vitro Diagnostics and Biogen’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Vitro Diagnostics -444.35% N/A -195.51% Biogen 13.81% 12.83% 8.01% Institutional & Insider Ownership 87.9% of Biogen shares are owned by institutional investors. 27.7% of Vitro Diagnostics shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations This is a breakdown of current ratings and recommmendations for Vitro Diagnostics and Biogen, as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vitro Diagnostics 0 0 0 0 0.00 Biogen 2 12 17 1 2.53 Biogen has a consensus target price of $220.57, indicating a potential upside of 8.57%. Given Biogen’s stronger consensus rating and higher probable upside, analysts plainly believe Biogen is more favorable than Vitro Diagnostics.
Valuation and Earnings This table compares Vitro Diagnostics and Biogen”s gross revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vitro Diagnostics $2.06 million N/A -$10.85 million ($2.21) -0.18 Biogen $9.89 billion 3.03 $1.29 billion $9.32 21.80 Biogen has higher revenue and earnings than Vitro Diagnostics. Vitro Diagnostics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
Summary Biogen beats Vitro Diagnostics on 11 of the 12 factors compared between the two stocks.
About Vitro Diagnostics (Get Free Report)
Vitro Diagnostics, Inc., doing business as Vitro Biopharma, focuses on the development, manufacture, and distribution of stem cell products and related tools for use in research, drug discovery, and clinical trials in the United States. Its stem cell technology includes cell lines, supporting products, and methods for generation and differentiation of stem cells into products for the treatment of diseases, such as heart disease, arthritis, multiple sclerosis, brain injury, autism, stroke, Parkinson's, and Alzheimer's diseases. The company also offers Tools for Stem Cell and Drug Discovery that provide researchers basic tools needed to advance stem cell technology, including stem cells and their derivatives; media for growth and differentiation of stem cells; and tools for measurement of stem cell quality, potency, and response to toxic agents. In addition, it offers MSC-Gro, a cell culture media product; MSC cell line for the treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, etc.; and testing and therapies related to endogenous stem cell activation. Further, the company provides diagnostic testing of stem cell activation and determination of stem cell functional status; and cell-based assays for discovery of novel stem cell activation agents and drugs for the treatment of osteoporosis. Vitro Diagnostics, Inc. was founded in 1986 and is based in Golden, Colorado.
About Biogen (Get Free Report)
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin’s lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin’s lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer’s disease and dementia, neuromuscular disorders, Parkinson’s disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Vitro Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitro Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
SANTA CLARA, Calif. & SUNNYVALE, Calif.--(BUSINESS WIRE)--Intel and Fortinet Collaborate to Advance Cybersecurity Innovation and Strengthen Global Supply Chain Resilience.
Upstart's (UPST +1.67%) business has come a long way in recent years. The fintech stock was one of the biggest losers in the post-pandemic bear market as its profits evaporated in 2022, but since then, it has regrouped, returned to generally accepted accounting principles (GAAP) profitability, and delivered strong growth.
However, that hasn't been enough to please investors, at least so far this year, and concerns about its business model and the departure of CEO Dave Girouard have hung over the company, despite its continuing to deliver solid results.
As a result, the stock fell 19% in the first six months of 2026, according to data from S&P Global Market Intelligence. As you can see from the chart below, shares fell sharply through the first quarter before recouping some of those losses in Q2.
UPST data by YCharts
What happened with Upstart this year Upstart actually jumped out of the gate, scoring a buy rating from Truist early in the year, crediting its advantage over traditional credit scoring and its AI foundation. However, by the end of January, the stock was in the red.
Upstart tumbled in February as it gave investors two bitter pills to swallow. First, it said that co-founder Dave Girouard was stepping down as CEO, to be replaced by co-founder and then-CTO Paul Gu, and it reported fourth-quarter earnings, delivering solid results but offering underwhelming guidance.
Overall growth in the quarter was impressive, with loans originated up 86% to 455,788 and revenue up 35% to $296.1 million as the company targets smaller loans and lower-risk borrowers, which offer less of a premium and have led to lower take rates. That figure beat estimates at $288.6 million.
On the bottom line, adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose from $38.8 million to $63.7 million, and it reported a GAAP profit per share of $0.17.
However, the company guided 2026 adjusted EBITDA margin to fall slightly from 22% to 21%, and investors also seemed worried about declining take rates, suggesting its lending partners aren't paying as much as they previously were. The stock fell 15% on Feb. 11 on the news and continued to decline from there.
The stock began to come back in April, popping 13% on April 15 in response to comments from Morgan Stanley that downplayed the risks in the private credit market, which have weighed on Upstart.
Shares pulled back again following the first-quarter earnings report in May, as it delivered solid growth but similar concerns persisted, including its declining take rate. More importantly, its adjusted EBITDA margin fell from 20% to 13%, driven by higher sales and marketing expenses, and its net loss widened from $2.4 million to $6.6 million.
Image source: Getty Images.
What's next for Upstart The company maintained its guidance for the year in the Q1 report, and CEO Paul Gu bought 50,000 shares of the stock the following week in May, which is typically a bullish signal.
Management also offered guidance through 2028, calling for a compound annual growth rate of around 35% during 2025-2028 and an adjusted EBITDA margin of 28%. If it can execute on that, the stock should move higher, but this is still a risky stock, especially considering that interest rates are now expected to move higher by the end of the year.
Vaxart (OTCMKTS:VXRT) held its 2026 Annual Meeting of Stockholders, where investors re-elected the company’s full slate of directors, ratified its auditor and rejected the company’s non-binding advisory proposal on executive compensation.
Mark Watson, Vaxart’s lead independent director and chair of the meeting, said proxies had been received for 110,631,100 of the company’s 242,044,838 outstanding shares of common stock entitled to vote as of the May 26, 2026, record date. That represented about 45.71% of eligible shares and constituted a quorum.
Stockholders Elect Directors, Reject Say-on-Pay Proposal Stockholders approved the election of James B. Breitmeyer, M.D., Ph.D.; Kevin P. Finney; Elaine J. Heron, Ph.D.; Steven Lo; W. Mark Watson, CPA; and David Wheadon, M.D., as directors to serve until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified.
Investors also approved the ratification of WithumSmith+Brown, PC as Vaxart’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
However, Watson said the company’s non-binding advisory vote on the compensation of named executive officers, referred to as the say-on-pay proposal, “did not pass.” Vaxart said it expects to report preliminary voting results, or final results if available, in a Form 8-K filing with the Securities and Exchange Commission within four business days of the meeting.
Management Says No Reverse Split Is Currently Planned Several stockholder questions focused on whether Vaxart would pursue a reverse stock split. Steven Lo, Vaxart’s president and chief executive officer, said the company is “not working on a reverse stock split at the present moment.”
Lo said Vaxart is focused on executing its corporate strategy, including completing its COVID-19 study and seeking potential norovirus partnerships. In response to a question about shareholder feedback, Lo said the company did not propose a reverse split at the annual meeting because it had heard from stockholders.
“Your opinion does matter,” Lo said.
Asked whether management anticipated calling a special meeting to revive a reverse split initiative, Lo said there is no current plan for a special meeting. He added that the company would prefer to execute its plan and, in a best-case scenario, see the stock price grow organically.
COVID-19 Program and BARDA-Backed Study Discussed Lo addressed questions about the 400-participant sentinel cohort data from Vaxart’s COVID-19 vaccine study. He said the company had announced top-line 12-month safety data from the cohort on July 6 and directed investors to the company’s press release for more detail.
Lo said Vaxart was “very happy” with the safety findings, including systemic effects, and said the Vaxart cohort “did much better than the mRNA” comparator on certain safety measures. He said the findings reinforced the safety of the company’s oral vaccine platform, noting that Vaxart has cumulatively dosed more than 1,000 subjects across studies.
On efficacy, Lo said the 400-participant cohort was not powered or designed to compare efficacy against mRNA vaccines. Still, he said the numbers were “certainly very close” and that Vaxart was encouraged by the results as it moves into a 5,000-subject cohort.
Lo said the sentinel 400 cohort targeted the XBB strain, matching the mRNA comparator used at that time. For the 5,000-participant cohort, he said the vaccine was updated to target the KP.2 strain, again matching the mRNA comparator. He also said the program uses Vaxart’s current second-generation constructs.
Regarding BARDA funding, Lo said Vaxart remains one of the few companies with a COVID-19 program agreement with BARDA after the agency canceled many projects in 2025. He said weekly interactions with BARDA could help position Vaxart for future opportunities, though any additional funding would depend on BARDA’s priorities and available budget.
Norovirus Partnerships Remain a Focus Lo said Vaxart has maintained ongoing conversations with various companies regarding a potential norovirus partnership. He emphasized that the company views the norovirus asset as highly valuable and would only be interested in offers that reflect what management sees as the full potential of the market.
“We only are going to be interested in offers that realize the full value of the potential of the norovirus market,” Lo said, adding that Vaxart believes it has one of the only norovirus vaccine candidates in development.
Asked about advancing the norovirus pipeline into a Phase II clinical study, Lo said the timing depends on additional funding and, at this point, would require a partnership commitment.
Cash Runway, Funding Efforts and Other Pipeline Updates Jeroen Grasman, Vaxart’s senior vice president and chief financial officer, said the company’s cash runway, as previously announced in its Form 10-Q, extends through the second quarter of 2027.
Lo said Vaxart continues to pursue non-dilutive funding opportunities, including through entities such as BARDA, the Gates Foundation and other government sources. He noted that the Gates Foundation previously funded Vaxart’s lactating mother study and said the company remains in dialogue with the foundation.
Management also addressed Vaxart’s licensing agreement with Altesa Biosciences for Vapendavir. Lo said Vaxart is eligible to receive up to $130 million in total payments if Altesa is successful, including tiered royalties ranging from low single digits to low double digits based on global net product sales. He directed investors to the company’s Form 10-K for additional details.
In response to concerns about the company’s share price, Lo said management and the board share investors’ disappointment. Watson added that the board is focused on creating value for all shareholders, including Vaxart’s large retail investor base.
Lo also said Vaxart remains in contact with the Dynavax/Sanofi team and that they are aware of the company’s COVID-19, norovirus and flu programs.
About Vaxart (OTCMKTS:VXRT) Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.
The company’s pipeline includes multiple vaccine candidates in various stages of development.
LOS ANGELES, July 20, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Zoetis Inc. (“Zoetis” or “the Company”) (NYSE: ZTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s securities between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before July 27, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Zoetis suffered from weakening veterinarian prescription growth for its Librela medication after the FDA issued safety warnings about neurological complications in dogs. The Company’s Trio product lost market share to competitors. The Company’s Apoquel and Cytopoint dermatology products lost market share to newly launched competing treatments for dogs. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Zoetis, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335 [email protected]
, /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced plans to launch Sorghum basis futures. Trading is expected to start on August 24, 2026, pending regulatory review.
Sorghum is a versatile commodity uniquely positioned to meet global demand from the domestic feed industry, the international export market and, more recently, biofuels.
The new basis contract reflects the price difference between sorghum and corn, two types of grain used in animal feed as well as ethanol feedstock. Sorghum's premium over corn usually signals international demand driving values higher. A deep discount compels domestic buyers to shift feed rations toward cheaper sorghum.
"While sorghum prices tend to track corn closely over extended macroeconomic cycles, geopolitical events and regional supply shifts can disrupt that relationship," said John Ricci, Managing Director and Global Head of Agricultural Products, CME Group. "In recent years, the sorghum-to-corn cash spread has experienced considerable volatility, swinging from sharp premiums to steep discounts. The Sorghum futures contract will provide market participants a precise instrument to hedge that basis risk."
The contracts will be physically delivered, with grain being loaded out by truck or rail from a network of elevators in Kansas, the nation's largest sorghum-producing state, by using the established Kansas City Hard Red Winter Wheat delivery network.
CME Group achieved record quarterly volume of 2.1 million contracts for Agricultural products in Q2 2026. Corn futures and options reached record open interest of 4.1 million contracts in Q2 2026, with the second highest quarterly volumes on record at 695,000 contracts traded.
The new Sorghum basis futures contracts will be listed and subject to the rules of CBOT. For more information on these products, please visit https://www.cmegroup.com/markets/agriculture/grains/sorghum.
As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products and metals. The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing.
CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc. CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC ("S&P DJI"). "S&P®", "S&P 500®", "SPY®", "SPX®", US 500 and The 500 are trademarks of Standard & Poor's Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners.
CHICAGO--(BUSINESS WIRE)--Motorola Solutions (NYSE: MSI) today announced that its APX NEXT XN P25 smart radio and XVN500 remote speaker microphone (RSM) are the first in the industry to achieve the National Fire Protection Association's (NFPA) 1930 certification. This latest set of standards supersedes the NFPA 1802 certification, representing the highest level of ruggedization with new software safety protocols for flexible volume control, clearer diagnostics and automatic audio battery alerts.
DENVER--(BUSINESS WIRE)--Royal Gold Provides Preliminary Financial Information and Details for the Release of Financial Results for the Second Quarter 2026.
Net Revenue: Record net revenues achieved.Pretax Profit Margin: 77%, marking the seventh consecutive quarter above 70%.Commissions: Increased by 30% year-over-
MCLEAN, Va.--(BUSINESS WIRE)--Capital One Financial Corporation (NYSE: COF) today announced net income for the second quarter of 2026 of $3.0 billion, or $4.73 per diluted common share, compared with net income of $2.2 billion, or $3.34 per diluted common share in the first quarter of 2026, and with net loss of $4.3 billion, or $(8.58) per diluted common share in the second quarter of 2025. Adjusted net income(1) for the second quarter of 2026 was $5.81 per diluted common share. "Our results in.
Earnings: $3 billion or $4.73 per diluted common share.Adjusted Earnings Per Share: $5.81.Revenue Growth: Increased 4% quarter-over-quarter.Non-Interest Expens
SEATTLE--(BUSINESS WIRE)--Expedia® today released its 2026 Island Hot List, revealing the Next Wave of island destinations gaining global momentum with searches for islands rising an average of 55% year-over-year,1 alongside social media mentions up 20%.2 Based on Expedia's search data, the Island Hot List highlights 10 fast-rising islands offering travelers an alternative to traditional hotspots, combining natural beauty, cultural depth, and sometimes better value. Expedia's 2026 Island Hot Li.
IRVING, Texas--(BUSINESS WIRE)-- #EnergySolutions--Fluor Awarded Front-End Engineering and Design for Petrochemical Facility in the Kingdom of Bahrain.
